50 Comparative evaluation of long- and short-read methylation-aware sequencing for CNS tumour diagnostics

Clicks: 22
ID: 326829
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #153 of 289 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 289 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction DNA methylation–based classification has transformed the diagnosis of central nervous system (CNS) tumours. However, methylation profiling alone is insufficient for definitive diagnosis and must be integrated with genomic alterations such as single nucleotide variants, structural variants, and gene fusions. Molecular diagnostics are therefore moving towards unified sequencing approaches capable of simultaneously capturing epigenomic and genomic information within a single assay. Rapid nanopore sequencing has demonstrated the feasibility of combined methylation and genomic profiling within an intraoperative timeframe. Illumina 5-base whole-genome sequencing is a recently released short-read technology that distinguishes methylated from unmethylated cytosines, enabling integrated epigenomic and genomic analysis. Here, we compare the diagnostic performance of these long- and short-read methylation-aware sequencing platforms in CNS tumours. Method We analysed a matched cohort of 30 CNS tumour samples previously characterised using a rapid nanopore diagnostic workflow. Illumina 5-base whole-genome sequencing was generated for each case, alongside conventional methylation array profiling. Tumour classification was performed using Random Forest, NanoDx, Sturgeon, and mnp-Flex, referencing Heidelberg classifier versions 11 and 12.8. Concordance between nanopore, Illumina 5-base, and standard-of-care methylation array classifications was assessed. Detection of diagnostically relevant genomic alterations, including single nucleotide variants, structural variants, and gene fusions, was compared across platforms. Results Illumina 5-base sequencing demonstrated strong concordance with rapid nanopore classifications and established methylation array diagnoses. Agreement was consistent across classifiers and reference versions. Both approaches identified key diagnostic genomic alterations, supporting comprehensive molecular characterisation from a single assay. Conclusion Integrated methylation-aware sequencing platforms enabling simultaneous epigenomic and genomic profiling show robust cross-platform concordance and clinical feasibility for CNS tumour diagnostics.
Reference Key
openalex_W7204490141 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Simon Deacon, Inswasti Cahyani, Nadine Holmes, Graeme Fox, Rory Munro, Satrio Wibowo, Thomas Murray, Mark Housley, Robert Goldspring, Sebastian Brandner, Felix Sahm, Stuart Smith, Simon Paine, Matthew Loose
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.020
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.020/70805879/noag172.020.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.